Diagnostic Efficacy of Tumor Markers Combined with HER-2 in Patients with Primary Gastric Cancer
Objective To study and analyze the clinical value of human epidermal growth factor receptor 2(HER-2)combined with human epidermal growth factor receptor 2 in the diagnosis of primary gastric cancer patients.Methods Sixty patients with primary gastric cancer who received treatment in Xuzhou Medical University Affiliated Pizhou Hos-pital from June 2017 to January 2023 were selected as the observation group,and sixty healthy subjects who under-went physical examination during the same period were selected as the reference group.Tumor marker level and HER-2 level were tested in both groups.The accuracy,sensitivity and specificity of tumor marker level,HER-2 level and tumor marker diagnosis,HER-2 diagnosis and tumor marker combined with HER-2 diagnosis were compared be-tween the two groups.Results The levels of carbohydrate antigen 19-9(CA19-9),carbohydrate antigen 125(CA125),carbohydrate antigen 72-4(CA72-4),carcinoembryonic antigen(CEA)and HER-2 in the observation group were(50.37±5.42)U/mL,(49.63±5.29)U/mL and(11.69±2.42)U/mL,(17.53±3.28)ng/mL,(20.65±3.58)ng/mL,signifi-cantly higher than those in the reference group,and the differences were statistically significant(t=60.451,59.408,30.833,35.147,18.848,all P＜0.05).The sensitivity and accuracy of tumor marker combined with HER-2 in the diag-nosis of primary gastric cancer were 98.33%and 97.50%,respectively,higher than those of tumor marker combined with HER-2 alone,the differences were statistically significant(both P＜0.05).Conclusion Both tumor markers and HER-2 can be used in the diagnosis of primary gastric cancer,and the combination of the two has a higher diagnostic efficiency.
万方数据
维普
